ERBB2 and cancer: Using a HER2-driven mouse model of breast cancer, Hosseiniet al. 14 showed that progesterone signaling subsequent to HER2 activation promotes cancer cell migration in early breast cancer lesions, ultimately leading to the majority of metastatic lesions observed in this experimental model.